The fact that the newest most specific ERK5 inhibitors (AX compounds) do not affect cancer cell proliferation [138] raises the questions of whether targeting ERK5 kinase activity is the proper therapeutic approach or, rather, targeting noncatalytic functions of ERK5 has to be pursued. The gene discussed is MAPK7; the disease is cancer.